Department of Breast Disease Diagnosis and Treatment Center, Jinan Central Hospital, Cheeloo College of Medicine, Shandong University; Department of Breast Disease Diagnosis and Treatment Center, Central Hospital Affiliated to Shandong First Medical University, Jinan Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Jinan, Shandong, China.
J Cancer Res Ther. 2022 Apr;18(2):567-575. doi: 10.4103/jcrt.jcrt_281_21.
This study analyzed the role of vasohibin-1 (VASH1) in human cancer outcomes. Relevant original studies on VASH1 expression in cancers were searched from PubMed, ClinicalKey, and Cochrane Library databases. A meta-analysis was performed to evaluate the role of VASH1 in clinicopathological characteristics and overall survival (OS) of patients with tumors. Statistical analysis was performed using the RevMan v. 5.3 software. Our meta-analysis results showed that patients with high VASH1 expression experienced a significantly poor prognosis with a hazard ratio (HR) of 1.69 (95% confidence interval [CI], 1.16- 2.46, P = 0.006) for OS, and an HR of 2.21 (95% CI, 1.32-3.68, P = 0.003) for progression-free survival. Furthermore, the high expression of VASH1 was significantly relevant to advanced tumor node metastasis stages. Thus, VASH1 is a potential biomarker to predict unfavorable clinical outcomes, serving as a potential tumor treatment target.
本研究分析了血管生成素样蛋白 1（VASH1）在人类癌症结局中的作用。从 PubMed、ClinicalKey 和 Cochrane Library 数据库中搜索了关于 VASH1 在癌症中表达的相关原始研究。采用 RevMan v.5.3 软件进行荟萃分析，以评估 VASH1 在肿瘤患者临床病理特征和总生存期（OS）中的作用。我们的荟萃分析结果表明，VASH1 高表达患者的预后明显较差，OS 的风险比（HR）为 1.69（95%置信区间[CI]，1.16-2.46，P=0.006），无进展生存期的 HR 为 2.21（95%CI，1.32-3.68，P=0.003）。此外，VASH1 的高表达与晚期肿瘤淋巴结转移分期显著相关。因此，VASH1 是预测不良临床结局的潜在生物标志物，可能成为肿瘤治疗的潜在靶点。
